X4 Pharmaceuticals
XFOR
95 hedge funds and large institutions have $219M invested in X4 Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 7 closing their positions.
557% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 7
490% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $1.85M
309% more capital invested
Capital invested by funds: $53.6M → $219M (+$165M)
127% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 11
70% more funds holding
Funds holding: 56 → 95 (+39)
0.7% more ownership
Funds ownership: 1.68% → 2.37% (+0.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$7.89M |
| 3 |
Millennium Management
New York
|
+$7.49M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.33M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$6.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.71M |
| 2 |
Axa
Paris,
France
|
-$1.66M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.42M |
| 4 |
JP Morgan Chase
New York
|
-$909K |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$740K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
101
Landscape Capital Management
Englewood,
New Jersey
| – | -$36.8K | -1,408 | Closed |
|
102
Renaissance Technologies
New York
| – | -$9K | -336 | Closed |
|
103
Osaic Holdings
Scottsdale,
Arizona
| – | -$460 | -18 | Closed |
|
XFOR Hedge Fund Activity: Q2 2023 in Review
95 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2023, worth a combined $219M — up 309% from $53.6M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new XFOR positions and 7 closed out — a net gain of 39 holders — while 25 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $15M. The largest seller was Perceptive Advisors, cutting an estimated $1.71M.
- 95 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2023, up from 56 in Q1 2023.
- Funds reported $219M of X4 Pharmaceuticals stock for Q2 2023, up 309% quarter-over-quarter.
- 46 funds opened new X4 Pharmaceuticals positions in Q2 2023 and 7 closed out, a net change of +39 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $15M added.
- The largest X4 Pharmaceuticals seller in Q2 2023 was Perceptive Advisors, an estimated $1.71M sold.
Based on aggregated 13F filings for Q2 2023.